Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Bayer’s Factor XIa inhibitor reduces repeat stroke risk by 26% in pivotal trial

Bayer presented the data from OCEANIC-STROKE at the International Stroke Conference 2026 in New Orleans.

Latest news

£1bn London Cancer Hub extension gets go-ahead amid UK life sciences push

The site will act as a global hub for cancer research as the UK looks to maintain its competitiveness in the life sciences market.

Lilly stops development of three drugs, including gene therapy

Eli Lilly has terminated the development of a gene therapy, an anti-CD19 antibody and a radioligand therapy.

Aicuris reports positive Phase III pritelivir results for HSV patients

The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.

TransCode and Quantum Leap seek FDA approval for Phase IIa TTX-MC138 trial

The Phase IIa clinical trial is scheduled to begin in the first half of 2026.

J.P. Morgan Healthcare Conference 2026 Report

The upcoming patent cliff, the impact of geopolitical and policy issues, and a changing deal environment were discussed at the J. P. Morgan Healthcare Conference 2026.